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accurate incidence and prevalence data, but incidence estimates were found to be 
5-12 people/million/year in US. AL amyloidosis is associated with early mortality 
(median survival < 3 years in many series) and a 42-64% rate of non-response or 
progression. Costly complications of AL amyloidosis include disease-related organ 
failure. For example, kidney involvement is present in about 70% of patients, and 
rates of dialysis in patients with AL amyloidosis range from 5-18% with mean total 
12-month healthcare costs (inpatient, outpatient and indirect costs) for patients 
receiving dialysis being $99,776. There are no disease specific patient-reported out-
come (PROs) tools developed for AL amyloidosis, but patients report severe psycho-
logical distress, anxiety and also experience unintentional weight loss. There are 
no consistent clinical guidelines for treatment of AL amyloidosis especially after 
relapse as no drug has received FDA or EMA approval for this indication. Overall, 
limited efficacy and significant toxicity are still major concerns with current ther-
apy. CONCLUSIONS: Limited epidemiologic and health outcomes data exist in the 
literature for relapsed or refractory AL amyloidosis. Treatment options are insuf-
ficient. New therapies which offer better clinical outcomes with less toxicity are 
needed to improve patient care.
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OBJECTIVES: To develop consensus statements outlining the impact of endoscopic 
linear stapling device stability on potential complications of thoracic surgery and 
the stress/concern of thoracic surgeons. METHODS: An 8-member expert panel 
of practicing thoracic surgeons representing eight different countries participated 
in a Delphi panel process that included two anonymous surveys. The first survey 
included binary, multiple-response, and Likert scale type questions, which were 
then converted into affirmative statements for the second survey if an adequate 
number of respondents answered similarly. Consensus was defined a priori when 
≥ 70% of respondents agreed with the affirmative statement in survey 2. RESULTS: 
All 8 panelists (100%) completed surveys 1 and 2. Panelists unanimously agreed an 
endoscopic linear stapling device with improved stability would result in less stress/
concern for critical firings, surgeries where a fellow is being trained, and robot-
assisted surgeries requiring an assistant. Across all tissue types, all panelists agreed 
that reduced unintentional tissue/structure damage and reduced tension on tissue 
being fired upon may result from use of an endoscopic linear stapling device that 
provides improvement in stability. The panel unanimously considered endoscopic 
linear stapling device stability to have more clinical importance in VATS thoracic 
surgery compared to open thoracic surgery. CONCLUSIONS: Improved endoscopic 
linear stapling device stability is a critical component of thoracic surgery that is 
likely to result in more frequent positive surgical outcomes when compared to a 
device with greater instability.
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OBJECTIVES: Brazil and Mexico present an attractive opportunity for biosimilar 
manufacturers. The majority of patients in these key Latin American markets rely 
entirely on government-sponsored healthcare. These public healthcare systems 
continually strive to limit any premium costs in favor of increasing their subopti-
mal coverage, particularly of biologics for oncology. This study explores the expected 
impact of more cost-effective biosimilar alternatives on coverage and prescribing for 
key oncology indications in Brazil and Mexico. METHODS: Across Brazil and Mexico, 
100 medical oncologists and 60 hematologists were surveyed regarding their views 
on biosimilars for breast cancer, colorectal cancer, and Non-Hodgkin’s lymphoma, 
and on current and expected biologics prescribing patterns. Additionally, 8 payers 
who influence reimbursement at a national or regional/institutional level were inter-
viewed. RESULTS: Up to 41% of biologics-eligible public patients with a given tumor 
type do not currently receive a biologic, according to surveyed physicians in Brazil and 
Mexico. Respondents largely attributed low access to limited coverage for oncology 
biologics. Surveyed physicians and interviewed payers anticipate improved access 
to biologics upon biosimilar launch and an overall reduced burden from oncology 
biologics to the healthcare systems. Although surveyed specialists indicate some 
initial caution regarding the bioequivalence of biosimilars, they nevertheless fore-
see widespread biosimilar uptake. In Brazil’s public sector, for example, respondents 
expect that 70% of Herceptin-eligible breast cancer patients will receive biosimi-
lar trastuzumab. CONCLUSIONS: Oncology biosimilars should find fertile terrain 
in Brazil and Mexico. Automatic substitution in the public sector is likely, although 
interchangeability regulations are currently under discussion in both markets. Cost-
effectiveness combined with pharmacovigilance and robust long-term safety data 
will play a major role in the continuous uptake of biosimilars versus brands, with the 
latter securing reasonable market share only if priced competitively.
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OBJECTIVES: The breakthrough therapy designation (BTD) pathway aims to expedite 
approval of drugs for serious and life-threatening conditions. BTD has been awarded 
to numerous oncology agents in development. This study assessed the likely impact 
of BTD on payer and prescriber perceptions of novel therapies, and its potential to 
cost and/or insufficient clinical advantage over other therapies. Interviewed EU5 
payers, meanwhile, demand robust demonstration of improvement over existing 
agents for favorable health technology assessment (HTA) of personalized therapies, 
and increasingly seek cost-sharing schemes. However, most surveyed US and EU5 
oncologists preferentially prescribe biomarker-driven agents where appropriate (e.g. 
80% of US respondents most frequently use crizotinib first-line for ALK-positive 
NSCLC), despite prior authorization and reauthorization being commonly required 
in the US, and country-specific cost-containment measures (e.g. physician budgets 
in Germany and prescribing monitoring registries in Italy) being key prescribing 
hurdles in the EU5. CONCLUSIONS: Strong, demonstrable advantages over existing 
agents and pricing compromises are required to secure favorable reimbursement for 
biomarker-driven treatment. While prescribers favor personalized medicine, payers 
require proven value for money. Manufacturers must strive to optimize trial design 
to help convince payers to see beyond the price tag, and be prepared to balance price 
expectations with uptake potential to optimize market access.
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OBJECTIVES: To characterize the usage of Temozolomide (TMZ) in a real-world set-
ting among patients with glioblastoma. METHODS: Adult patients diagnosed with 
malignant brain cancer (ICD9-CM, 191.XX), who underwent brain-related surgery 
90 days prior to the first TMZ dose and had ≥ 24 months of continuous enrollment, 
were identified in the IMS Pharmetrics Lifelink Plus claims database. The TMZ + 
radiation subgroup was used to reflect glioblastoma patients and differentiate them 
from patients with lower-grade gliomas. Descriptive statistics were generated for 
patient demographics, insurance-related variables, co-diagnoses, concomitant 
medications, chemotherapy cycle-duration, and TMZ dose. The index date was 
defined as the first claim for TMZ, and certain variables were assessed for pre- 
and post-12 month periods. Statistical comparisons between pre- and post-index 
were performed using McNemar’s tests. RESULTS: A total of 1,126 patients met the 
inclusion criteria and the mean age was 52.7 yrs. (SD= 10.9). There was a significant 
increase in the use of concomitant medications (antianxiety, antidepressants, and 
antiemetic) as well as co-diagnoses (depression, fatigue, seizure/epilepsy, and hear-
ing loss) in the post-index period (p< 0.001). However, in this same period, corticos-
teroid and pain medication use significantly decreased as did the co-diagnoses of 
aphasia and headache (p< 0.001). TMZ mean starting dose, duration, and number 
of maintenance phase cycles was 154.4 mg (SD= 77.9), 46 days (SD= 12), and 7 cycles 
(SD= 3), respectively. Following the first dose, 73% of patients experienced a TMZ dose 
increase. CONCLUSIONS: Post-index, patients experienced a complex change in 
both concomitant medications and co-diagnoses, possibly reflecting both a decrease 
in tumor mass and side effects of the TMZ + radiation therapy. These initial findings 
warrant further investigation of TMZ as real-world standard-of-care in glioblastoma.
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OBJECTIVES: To characterize patients and treatment approaches relative to BRAF 
gene mutation testing. METHODS: An analysis of patient characteristics, diagnostic 
and treatment including BRAF testing, age, co-morbidities, number of tumor sites, 
hospital vocation and type of therapy used was conducted using the information 
included in the IMS Brogan Enhanced Tumor Study database from October 2013 to 
September 2014. RESULTS: Out of 343 stage IV melanoma patients, 239 were tested 
for BRAF mutations. 57% (136 pts.) were BRAF positive, 36% (87 pts.) BRAF negative 
and for 7% (16 pts.) results were not reported. Patients who were tested for BRAF 
tended to be less than 50 years of age (46% vs. 16%, p< 0.01), have none or only 1 
co-morbidity (87% vs. 70%, p< 0.01), have only 1 metastasis (34% vs. 45%, p< 0.05), 
and treated in an academic facility (74% vs. 50%, p< 0.01) compared to those who 
were not tested. BRAF negative patients were more often treated with ipilimumab 
compared to those who were not tested (42% vs. 10%, p< 0.01). CONCLUSIONS: 
Patients characteristics emerged as an important factor for determining diagnostic 
and treatment protocols for metastatic melanoma patients in Canada. Younger 
patients and those with more favorable disease characteristics are more likely to 
be tested for BRAF mutations and treated with ipilimumab in those without BRAF 
mutation. BRAF testing appears to be more prevalent in academic centers than in 
community hospitals.
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OBJECTIVES: To conduct a systematic literature review on relapsed or refractory AL 
amyloidosis, focusing on clinical outcomes, epidemiology, health-related quality-
of-life (HRQoL) and economic aspects. METHODS: MEDLINE and EMBASE databases 
were searched for English-language articles published in the last 10 years using 
search terms including “Primary/Systemic amyloidosis”, “epidemiology/prevalence/
incidence”, “therapeutics/drug therapy/outcome”, ”patient-reported/quality-of-
life/satisfaction and “economics/cost” etc. Search results were manually reviewed, 
and relevant studies were selected for inclusion as appropriate. Additional refer-
ences were obtained from clinical conferences and the reference lists of selected 
articles. RESULTS: 1,141 articles were initially retrieved, and 58 were included in 
the current review. Given the rare nature of the disease, it was difficult to obtain 
